Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Medina Urrutia, Aida ^a   Posadas Romero, Carlos ^a   Posadas Sánchez, Rosalinda ^a   Jorge Galarza, Esteban ^a   Villarreal Molina, Teresa ^b   González Salazar, María del Carmen ^a   Cardoso Saldaña, Guillermo ^a   Vargas Alarcón, Gilberto ^a   Torres Tamayo, Margarita ^a   Juárez Rojas, Juan Gabriel ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

Author keywords

Adiponectin; Free fatty acids; Insulin resistance; Visceral fat

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADIPONECTIN; ADULT; AGED; BIOMARKERS; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED;

EID: 84924322756     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0184-5     Document Type: Article

References (35)

1. World and Health Organization (2014). The 10 leading causes of death in the world, 2000 and 2012 [WWW document]. URL www.who.int/mediacentre/factsheets/fs310/en/ .
2. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906-12.
3. Ortega FB, Lee DC, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34:389-97.
4. Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152-62.
5. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48.
6. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-94.
7. Messier V, Karelis AD, Prud'homme D, Primeau V, Brochu M, Rabasa-Lhoret R. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity. 2010;18:911-7.
8. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27:S6-11.
9. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 2012;425:560-4.
10. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152:673-84.
11. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol. 2012;57:91-7.
12. Miller MR, Pereira RI, Langefeld CD, Lorenzo C, Rotter JI, Chen YD, et al. Levels of free fatty acids (FFA) are associated with insulin resistance but do not explain the relationship between adiposity and insulin resistance in Hispanic Americans: the IRAS Family Study. J Clin Endocrinol Metab. 2012;97:3285-91.
13. Villarreal-Molina T, Posadas-Romero C, Romero-Hidalgo S, Antúnez-Argüelles E, Bautista-Grande A, Vargas-Alarcón G, et al. The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study. PLoS One. 2012;7:e49285.
14. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol.The Lipid Research Clinics Prevalence Study. JAMA. 1986;256:2372-7.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
16. American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care. 2010;33:S11-61.
17. Kvist H, Chowdhury B, Grangard U, Tylén U, Sjöström L. Total and visceral adipose-tissue volumes derived from measurement with computed tomography in adult men and women: predicted equations. Am J Clin Nutr. 1988;48:1351-61.
18. Oka R, Kobayashi J, Inazu A, Yagi K, Miyamoto S, Sakurai M, et al. Contribution of visceral adiposity and insulin resistance to metabolic risk factors in Japanese men. Metabolism. 2010;59:748-54.
19. Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I. Relationships between circulating adiponectin levels and fat distribution in obese subjects. J AtherosclerThromb. 2011;18:592-5.
20. Matsushita Y, Nakagawa T, Yamamoto S, Kato T, Ouchi T, Kikuchi N, et al. Adiponectin and visceral fat associate with cardiovascular risk factors. Obesity. 2014;22:287-91.
21. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target formetabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.
22. Aguilar-Salinas CA, García EG, Robles L, Riaño D, Ruiz-Gomez DG, García-Ulloa AC, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93:4075-9.
23. Nakamura MT. YudellBE Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res. 2014;53:124-44.
24. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493-6.
25. He H, Ni Y, Chen J, Zhao Z, Zhong J, Liu D, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res. 2010;155:71-7.
26. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004;18:2024-34.
27. Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E. Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. J Biol Chem. 2005;280:34786-95.
28. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55-63.
29. Plaisance EP, Grandjean PW, Judd RL, Jones KW, Taylor JK. The influence of sex, body composition, and nonesterified fatty acids on serum adipokine concentrations. Metabolism. 2009;58:1557-63.
30. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014;28:119-30.
31. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
32. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-9.
33. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.
34. Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM. Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol. 2013;12:170.
35. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab. 2007;92:2665-71.